Evolving Strategies for the Management of Hereditary Angioedema – A Patient-Centered Approach With Real-World Examples
Released On
August 1, 2025
Expires On
August 1, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Allergy & Immunology
Topics
Allergies, Immunology
Provider Statement:
Provided by Integrity CE, LLC.
Disclosure of Commercial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of allergists, immunologists, nurse practitioners, physician assistants, and other healthcare providers who manage patients with hereditary angioedema (HAE).
Program Overview
HAE is a rare autosomal-dominant disorder that affects approximately 1 in 50,000 people worldwide. Individuals with HAE typically experience recurrent painful swelling of the extremities, face, or genitals, in addition to gastrointestinal attacks and potentially fatal laryngeal edema. Furthermore, these swelling episodes are often associated with disfigurement, significant functional impairment, and decreased quality of life (QOL). Despite the existence of specific diagnostic criteria, diagnosis may be delayed by up to 15 years, leading to delays in optimal treatment with available on-demand and prophylactic therapies. Additionally, several novel agents are in development. Given the range of treatment options (eg, formulations, administration routes, dosing strategies), timely diagnosis and personalized treatment plans and a shared decision-making approach are essential to ensure appropriate utilization of prescribed treatment and quick recovery from attacks.
Join our expert faculty in this case-based activity to explore a tailored approach that not only enhances treatment adherence and efficacy but also significantly improves patient QOL, ensuring that clinicians can better address the complexities of HAE to promote improved health outcomes and reduced morbidity.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Apply guideline-recommended strategies to accurately identify patients with HAE
- Analyze and compare approved and emerging treatment options for managing HAE effectively
- Utilize shared decision-making and validated assessment tools in the development of treatment plans for patients with HAE
Faculty
Maeve O'Connor, MD, FACAAI, FAAAAI, FACP
Clinical Assistant Professor, University of North Carolina - Charlotte Department of Public Health Sciences
Clinical Adjunct Professor, University of Arizona-Tucson
Department of Integrative Medicine
Medical Director, Integrative Allergy & Immunology Care, LLC
Medical Director and Principal Investigator, Allergy Asthma & Immunology Research Institute
Chief Medical Officer, Consortium of Independent Immunology Clinics
Chief Medical Officer, Alexander Innovations International
Nicholas C. Kolinsky, DO
Clinical Adjunct Faculty
Allergy and Immunology
Lincoln Memorial University-DeBusk College of Osteopathic Medicine
Harrogate, Tennessee
President-Elect, Tennessee Society of Allergy, Asthma, and Immunology
Knoxville, Tennessee
Neetu Talreja, MD, FAAAAI, FACAAI
Board Certified Pediatric and Adult Allergist and Immunologist
The Allergy Group
Boise, Idaho
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Nicholas C. Kolinsky, DO
Advisory Boards: ADMA Biologics, AstraZeneca, Hikma Pharmaceuticals, KalVista Pharmaceuticals,
Novartis Pharmaceuticals, Pharming
Speaker: Amgen, AstraZeneca, CSL Behring, GlaxoSmithKline, Hikma Pharmaceuticals, Sanofi Pharmaceuticals
Maeve O’Connor, MD, FACAAI, FAAAAI, FACP
Advisory Boards: AADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring,
GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda
Consultant/Speaker: ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring,
GlaxoSmithKline, KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda
Research:ADMA, Amgen, AstraZeneca, Blueprint, Cogent, CSL Behring, GlaxoSmithKline,
KalVista, Novartis, Optinose, Pharming, Regeneron, Sanofi, Takeda
Neetu Talreja, MD, FAAAAI, FACAAI
Advisory Boards: Regeneron, Novartis, Celldex, Incyte
Speaker: ARS Pharmaceuticals
Research: 9Meters, Abbvie, Allakos, Amgen, Anaptybio, Arcutis, Arena, ARS Pharma,
AstraZeneca, Biohaven, Blueprint, Braintree Laboratories Inc., Castle Biosciences Inc.,
Celldex Therapeutics, Cindome Pharma, Inc., Eli Lilly and Company, Escient Pharmaceuticals, Inc.,
Evommune Inc., Gossamer, GlaxoSmithKline, Incyte Co., Jasper Therapeutics Inc., Knopp,
Nerre, Novartis Pharmaceuticals, Pearl Therapeutics, Pfizer, Phathom, Regeneron Pharmaceuticals,
Sanofi-Aventis Recherche & Developpement, Seres, Teva Branded Pharmaceutical Products R&D,
Uniquity One, Upstream Bio, Inc
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of August 1, 2025 through August 1, 2026, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].